Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2 1

Status

Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 58Recurrence 7Neoplasms, Plasma Cell 6Lymphoma 6Immunoglobulin Light-chain Amyloidosis 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Myeloid, Acute 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thalassemia 1Sarcoma, Myeloid 1Renal Insufficiency 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1

Interventions

Dexamethasone 7Bortezomib 6Cyclophosphamide 5daratumumab 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3venetoclax 2dexamethasone acetate 2dexamethasone 21-phosphate 2belantamab mafodotin 2auricularum 2X-Rays 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Calcium Dobesilate 2Biopsy 2ixazomib 1Tissue Banks 1Stem Cell Transplantation 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Bortezomib × 90 days × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Peking University People's Hospital

Phase NA Recruiting
41 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Peking University People's Hospital

Recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡